Sign Out
Mefenamic acid, administered alone, has not been shown to affect blood-clotting mechanisms. However, a prolongation of the prothrombin time has been shown to occur when mefenamic acid is administered to patients receiving coumarin anticoagulants due to an interaction with other plasma protein-binding drugs. When mefenamic acid and coumarin anticoagulants are administered concurrently, the prothrombin time should be checked and the dosage of the anticoagulant modified accordingly. Concurrent therapy with other plasma protein-binding drugs may also necessitate a modification in dosage.
Use in Pregnancy: Safety in pregnancy has not been established.
Continue with Google